| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/01/2004 | EP1452594A1 Inducer for differentiation of embryo stem cells into ectodermal cells, method of obtaining the same and use thereof |
| 09/01/2004 | EP1452586A1 METHOD OF INDUCING DIFFERENTIATION OF MESODERMAL STEM CELLS, ES CELLS OR IMMORTALIZED CELLS INTO NERVOUS SYSTEM CELLS |
| 09/01/2004 | EP1452527A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation |
| 09/01/2004 | EP1452524A1 "2-oxo-1-pyrrolidine derivative and its pharmaceutical uses" |
| 09/01/2004 | EP1452522A2 Novel compounds and compositions as protease inhibitors |
| 09/01/2004 | EP1451590A2 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases |
| 09/01/2004 | EP1451337A2 Nogo receptor-mediated blockade of axonal growth |
| 09/01/2004 | EP1451308A2 Therapeutic use of aziridino compounds |
| 09/01/2004 | EP1451307A2 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/01/2004 | EP1451226A1 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| 09/01/2004 | EP1451212A2 Structural and cytoskeleton-associated proteins |
| 09/01/2004 | EP1451202A1 Aryl fused azapolycyclic compounds |
| 09/01/2004 | EP1451197A1 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo- 3.2.2 nonane derivatives, preparation and therapeutic use thereof |
| 09/01/2004 | EP1451192A1 Novel crystalline compound |
| 09/01/2004 | EP1451191A1 Thioether substituted imidazoquinolines |
| 09/01/2004 | EP1451190A1 Triazolo(4,3-a)pyrido(2,3-d)pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof |
| 09/01/2004 | EP1451189A1 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo- 3.2.2]nonane derivatives, preparation and therapeutic use thereof |
| 09/01/2004 | EP1451188A1 4-(oxadiazol-3-yl)-1,4-diazabicyclo 3.2.2]-nonane derivatives, preparation and therapeutic use thereof |
| 09/01/2004 | EP1451187A1 Amide substituted imidazopyridines |
| 09/01/2004 | EP1451186A2 Urea substituted imidazopyridines |
| 09/01/2004 | EP1451177A1 Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine |
| 09/01/2004 | EP1451176A2 Benzazepine derivatives and their use as 5-ht ligands |
| 09/01/2004 | EP1451174A2 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers |
| 09/01/2004 | EP1451173A2 Piperidines |
| 09/01/2004 | EP1451172A1 Therapeutic isoquinoline compounds |
| 09/01/2004 | EP1451167A1 Phenylalkynes |
| 09/01/2004 | EP1451166A1 Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof |
| 09/01/2004 | EP1451165A1 Substituted benzoxazoles and analogues as estrogenic agents |
| 09/01/2004 | EP1451164A2 Amide derivatives having improved solubility |
| 09/01/2004 | EP1451161A1 Imidazopyridines, pyrimidines and triazines for enhancing cognition as gaba-a alpha 5 receptor subtype ligands |
| 09/01/2004 | EP1451159A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof |
| 09/01/2004 | EP1451158A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties |
| 09/01/2004 | EP1451157A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties |
| 09/01/2004 | EP1451156A1 4-aminoquinoline compounds |
| 09/01/2004 | EP1451154A2 Inhibitors of cytosolic phospholipase a2 |
| 09/01/2004 | EP1451153A1 Nk1 antagonists |
| 09/01/2004 | EP1451146A1 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof |
| 09/01/2004 | EP1451145A1 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof |
| 09/01/2004 | EP1450843A2 Use of thymulin-like peptides for making pain-relieving medicines |
| 09/01/2004 | EP1450837A2 Interleukin-1 receptors in the treatment of diseases |
| 09/01/2004 | EP1450836A2 Method for short-term and long-term drug dosimetry |
| 09/01/2004 | EP1450826A1 Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium |
| 09/01/2004 | EP1450824A1 Pharmaceutical composition |
| 09/01/2004 | EP1450817A1 Use of pregnane-diones or diols as neuropathic analgesic agents |
| 09/01/2004 | EP1450816A2 Method of treating disorder related to high cholesterol concentration |
| 09/01/2004 | EP1450811A2 2-aryl pyrrolopyrimidines for a1 and a3 receptors |
| 09/01/2004 | EP1450807A1 Method of treating depression with delta receptor agonist compounds |
| 09/01/2004 | EP1450801A2 2-aminoquinoline compounds |
| 09/01/2004 | EP1450797A1 Benzothiazole derivatives |
| 09/01/2004 | EP1450796A1 Benzothiazole derivatives |
| 09/01/2004 | EP1450795A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease |
| 09/01/2004 | EP1450792A1 Benzazole derivatives for the treatment of scleroderma |
| 09/01/2004 | EP1450783A1 New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma |
| 09/01/2004 | EP1450780A1 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation |
| 09/01/2004 | EP1450779A1 Method for treating autoimmune diseases |
| 09/01/2004 | EP1450777A1 Pharmaceutical composition containing chalcone or its derivatives for matrix metalloproteinase inhibitory activity |
| 09/01/2004 | EP1450776A1 Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof |
| 09/01/2004 | EP1450773A1 Transdermal therapeutic system provided with improved long-term carrying comfort |
| 09/01/2004 | EP1450772A1 Micronized film-forming powder comprising an active substance |
| 09/01/2004 | EP1450770A2 Pharmaceutical composition comprising a 5ht1 receptor agonist |
| 09/01/2004 | EP1450769A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 09/01/2004 | EP1450768A1 Oral controlled release forms useful for reducing or preventing nicotine cravings |
| 09/01/2004 | EP1450764A2 Dopamine agonist formulations for enhanced central nervous system delivery |
| 09/01/2004 | EP1450750A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase |
| 09/01/2004 | EP1450629A1 Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof |
| 09/01/2004 | EP1274675B1 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system |
| 09/01/2004 | EP1242410B1 Novel compounds |
| 09/01/2004 | EP1228024B1 Novel hydronaphthalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 09/01/2004 | EP1223914B1 Orally distintegrating composition comprising mirtazapine |
| 09/01/2004 | EP1221443B1 Substituted imidazolidinone derivatives |
| 09/01/2004 | EP1194138A4 Nutritional supplements |
| 09/01/2004 | EP1165528B1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 09/01/2004 | EP1127058B1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 09/01/2004 | EP1115738A4 Synthesis of cyclic peptides |
| 09/01/2004 | EP1047769B1 Novel therapeutic uses of heterologous superoxide dismutase (hsd), and method for selecting said hsd |
| 09/01/2004 | EP1027067B1 Use of substances having oxytocin activity for the preparation of medicaments for the treatment of affective pain syndromes |
| 09/01/2004 | EP0944621B1 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists |
| 09/01/2004 | EP0942729B1 Use of nk-1 receptor antagonists for treating stress disorders |
| 09/01/2004 | EP0923530B1 Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
| 09/01/2004 | EP0880502B1 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents |
| 09/01/2004 | EP0610254B1 Glial derived neurotrophic factor |
| 09/01/2004 | CN1526014A Paramyxovirus vectors for introducing foreign genes into skeletal muscle |
| 09/01/2004 | CN1525978A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/01/2004 | CN1525974A Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine A2a receptor and their use as medicaments |
| 09/01/2004 | CN1525973A Dihydroimidazo[5,1-a]-beta-carboline derivatives, method for preparing same and use thereof as medicine |
| 09/01/2004 | CN1525972A Hetero-bicyclic crf antagonists |
| 09/01/2004 | CN1525955A Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments |
| 09/01/2004 | CN1525866A Treatment using neublastin polypeptides |
| 09/01/2004 | CN1525865A Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| 09/01/2004 | CN1525860A Novel therapeutic use of a thienylcyclohexylamine derivative |
| 09/01/2004 | CN1525858A A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent for modulating cholinergic function |
| 09/01/2004 | CN1525851A Abuse-resistant controlled-release opioid dosage form |
| 09/01/2004 | CN1524872A Active ingredient of jasmine root, extracting method and uses thereof |
| 09/01/2004 | CN1524857A Tartrate salt of a substituted dipeptide as growth hormone secretagogue |
| 09/01/2004 | CN1524852A Novel compounds with analgesic effect |
| 09/01/2004 | CN1524850A Histone de-acetylase inhibitor, preparation and application of pharmaceutical preparations of the same |
| 09/01/2004 | CN1524538A Chinese traditional medicine composition for treating epilepsy |
| 09/01/2004 | CN1524519A Lysine hydrochloride powder and injection preparation |
| 09/01/2004 | CN1164759C Method for preparing corydamine by biotransformation and use thereof in preparing analgesic |
| 09/01/2004 | CN1164590C Imiadazodiazepine derivative |